on Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler: US Consul Visits Braunschweig Radiopharmaceutical Facility
On April 10, 2025, US Consul General Jason Chue toured Eckert & Ziegler's Braunschweig site, familiarizing himself with their radiopharmaceutical production for cancer diagnostics and therapy. Eckert & Ziegler, an isotope specialist, earns approximately 40% of its revenue from the USA, with production facilities across three states and over 170 employees.
The company manufactures Theralugand® (lutetium-177 chloride) for treating neuroendocrine tumors and metastatic prostate cancer. To meet the rising global demand for lutetium-177, Eckert & Ziegler is investing around EUR 10 million to expand their US production capabilities in Wilmington, expected operational by 2027.
US Consul General Chue praised the company as a model of transatlantic collaboration, contributing to cancer treatment advancements worldwide. Dr. Harald Hasselmann, Chairman of the Executive Board, emphasized their commitment to enhancing nuclear medicine therapies through quality radionuclides.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news